



## APPENDIX 4C – JUNE 2018 QUARTER

**Brisbane, Australia 27<sup>th</sup> July 2018** Factor Therapeutics Limited (ASX: FTT), an Australian biomedical company developing therapeutics for advanced wound care, has released its Appendix 4C (Quarterly Cashflow Statement) for June 2018 Quarter.

- Cash reserves of \$6.413 million at the end of the Quarter
- Quarterly operating expenditure of \$3.4 million, with total spend on direct R&D activities at approximately \$2.3 million
- R&D tax rebate of \$1.2 million received during the quarter, for eligible R&D activities undertaken in the period ending 31 December 2017
- During the quarter the Company completed a 1 for 7, fully underwritten non-renounceable Entitlement Offer for \$3.846 million (after transaction costs)

### Key Activities

- Presentations at the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC highlighting the Company's technology and design of the Phase 2 study of VF001 in venous leg ulcers
- Finalisation of the Phase 2 clinical trial analysis plan in consultation with external statistical experts
- Completed full recruitment of the Phase 2 clinical trial in mid-July

---

### For Further Information Contact:

Dr. Rosalind Wilson  
Chief Executive Officer  
Factor Therapeutics Limited  
[r.wilson@factor-therapeutics.com](mailto:r.wilson@factor-therapeutics.com)

### About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

**Name of entity**

FACTOR THERAPEUTICS LIMITED

**ABN**

45 101 955 088

**Quarter ended ("current quarter")**

30-June-2018

**Consolidated statement of cash flows**

	Current quarter \$A'000	Year to date (6 months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	40	62
1.2 Payments for		
(a) research and development	(2,293)	(3,768)
(b) product manufacturing and operating costs	(199)	(257)
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(599)	(925)
(f) administration and corporate costs	(306)	(503)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	27	33
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,226	1,226
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from/(used in ) operating activities</b>	<b>(2,104)</b>	<b>(4,132)</b>

**2. Cash flows from investing activities**

2.1 Payments to acquire:		
(a) property, plant and equipment	(3)	(3)
(b) businesses (see item 10)	-	-
(c) investments	-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter</b>	<b>Year to date</b>
	<b>\$A'000</b>	<b>(6 months)</b>
	<b>\$A'000</b>	<b>\$A'000</b>
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 <b>Net cash from/(used in) investing activities</b>	<b>(3)</b>	<b>(3)</b>
<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	4,172	4,172
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(326)	(339)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 <b>Net cash from/(used in) financing activities</b>	<b>3,846</b>	<b>3,833</b>
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	4,625	6,642
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(2,104)	(4,132)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(3)	(3)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	3,846	3,833

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date</b>
		<b>\$A'000</b>	<b>(6 months)</b>
			<b>\$A'000</b>
4.5	Effect of movement in exchange rates on cash held	49	73
4.6	<b>Cash and cash equivalents at end of quarter</b>	6,413	6,413

		<b>Current quarter</b>	<b>Previous quarter</b>
		<b>\$A'000</b>	<b>\$A'000</b>
5.	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1	Bank Balances	2,549	3,801
5.2	Call deposits	3,864	2,841
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>6,413</b>	<b>6,642</b>

		<b>Current quarter</b>
		<b>\$A'000</b>
6.	<b>Payments to directors of the entity and their associates</b>	
6.1	Aggregate amount of payments to the parties included in item 1.2	(93)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
	Payments to directors includes directors fees and executive directors salaries.	

		<b>Current quarter</b>
		<b>\$A'000</b>
7.	<b>Payments to related entities of the entity and their associates</b>	
7.1	Aggregate amount of payments to the parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

**8. Financing facilities available**  
*Add notes as necessary for an understanding of the position*

	Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

**9. Estimated cash outflows for next quarter**

- 9.1 Research and development
- 9.2 Product manufacturing and operating costs
- 9.3 Advertising and marketing
- 9.4 Leased assets
- 9.5 Staff costs
- 9.6 Administration and corporate costs
- 9.7 Other - Transaction costs related to issue of shares
- 9.8 Total estimated cash outflows**

	\$A'000
9.1 Research and development	1,757
9.2 Product manufacturing and operating costs	382
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	456
9.6 Administration and corporate costs	452
9.7 Other - Transaction costs related to issue of shares	-
<b>9.8 Total estimated cash outflows</b>	<b>3,047</b>

**10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)**

- 10.1 Name of entity
- 10.2 Place of incorporation or registration
- 10.3 Consideration for acquisition or disposal
- 10.4 Total net assets
- 10.5 Nature of business

	Acquisitions	Disposals
10.1 Name of entity	N/A	N/A
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

**Compliance statement**

<sup>1</sup> This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

<sup>2</sup> This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed  
(Company Secretary)



Date: 27-July-2018

Print name: Melanie Farris

**Notes**

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.